PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.

ABSTRACT:

Background

Intravascular large B-cell lymphoma (IVLBCL) is a rare form of diffuse large B-cell lymphoma (DLBCL) arising in extranodal sites. PD-L1 expression of tumor cells has been reported in IVLBCL cells, but its clinicopathological relevance remains to be elucidated.

Aims

This study was aimed to reveal the characteristics of PD-L1⁺ IVLBCL.

Methods and results

Neoplastic PD-L1 expression was examined in 34 cases of IVLBCL and clinicopathological characteristics between patients with PD-L1⁺ and PD-L1^- IVLBCL were compared. We assessed PD-L1 expression with SP142 antibody. Twelve (35%) of 34 cases showed positivity for PD-L1. The PD-L1⁺ group had significantly lower survival rates compared to the PD-L1^- group. Th

SUBMITTER: Suzuki Y 

PROVIDER: S-EPMC7333862 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature